Form 4: Citius Oncology Director Granted Stock Options and Files Power of Attorney

Suren G. Dutia, a director of Citius Oncology, Inc., was granted stock options and filed a power of attorney related to SEC filings.

Summary

• Suren G. Dutia, a director of Citius Oncology, Inc., was granted stock options on August 12, 2024.
• The options grant was for 150,000 shares with an exercise price of $2.15.
• The options vest immediately and expire on July 5, 2033.
• Dutia also filed a Power of Attorney, effective August 13, 2024, appointing Jaime Bartushak, Alexander M. Donaldson, and Lorna A. Knick to handle SEC filings on his behalf.
• This Power of Attorney covers Forms ID, 3, 4, 5, and Schedules 13D/13G.

Sentiment

Score: 5

Explanation: The document describes routine administrative and compensation matters, so the sentiment is neutral.

Positives

• The granting of stock options to a director could be seen as a positive sign, aligning the director's interests with those of the shareholders.

Future Outlook

The Power of Attorney remains in effect until Suren G. Dutia is no longer required to file Forms ID, 3, 4 and 5 and Schedules 13D/13G, or until revoked.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders. The filing of a Power of Attorney is a standard administrative procedure.

Stakeholder Impact

• The granting of stock options may have a minor positive impact on shareholder sentiment.

Key Dates